• Return to Headlines

Progenics Pharm Shares Down 25.8% Since SmarTrend's Sell Call (PGNX)

By Amy Schwartz

SmarTrend identified a Downtrend for Progenics Pharm (NASDAQ:PGNX) on September 10th, 2018 at $7.30. In approximately 2 months, Progenics Pharm has returned 25.84% as of today's recent price of $5.41.

In the past 52 weeks, Progenics Pharm share prices have been bracketed by a current low of $0.00 and a high of $9.42 and are now at $0.00. The 200-day and 50-day moving averages have moved 0.4% lower and 3.92% lower over the past week, respectively.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Progenics Pharm.

Log in and add Progenics Pharm (PGNX) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights progenics pharm

Ticker(s): PGNX